New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
10:00 EDTARIA, VNO, MSO, IZEA, FST, NEM, SEAC, ITMN, SUNS, DWA, VLRS, VLP, FMS, HUM, JAZZ, JNPR, NIHD, PSXP, SWY, TOL, BOOM, DRHOn The Fly: Analyst Downgrade Summary
DiamondRock (DRH) downgraded to Neutral from Buy at ISI Group... Dynamic Materials (BOOM) downgraded to Neutral from Overweight at JPMorgan... Fresenius Medical (FMS) downgraded to Neutral from Buy at UBS... Humana (HUM) downgraded to Sell from Neutral at Citigroup... Jazz Pharmaceuticals (JAZZ) downgraded to Hold from Buy at Cantor... Juniper (JNPR) downgraded to Neutral from Overweight at Piper Jaffray... NII Holdings (NIHD) downgraded to Neutral from Outperform at Macquarie... Phillips 66 Partners (PSXP) downgraded to Neutral from Outperform at Credit Suisse... Safeway (SWY) downgraded to Neutral from Overweight at JPMorgan... Toll Brothers (TOL) downgraded to Market Perform from Outperform at Keefe Bruyette... Valero Energy Partners (VLP) downgraded to Neutral from Outperform at Credit Suisse... Volaris (VLRS) downgraded to Hold from Buy at Deutsche Bank... Vornado (VNO) downgraded to In-Line from Outperform at Imperial Capital... Martha Stewart (MSO) downgraded to Hold from Buy at Noble Financial... IZEA (IZEA) downgraded to Neutral from Buy at Merriman... Forest Oil (FST) downgraded to Market Perform from Outperform at Wells Fargo... Newmont Mining (NEM) downgraded to Hold from Buy at Argus... SeaChange (SEAC) downgraded to Neutral from Buy at Dougherty... InterMune (ITMN) downgraded to Market Perform from Outperform at Leerink... Solar Senior Capital (SUNS) downgraded to Hold from Buy at BB&T... DreamWorks Animation (DWA) downgraded to Underweight from Neutral at Piper Jaffray... ARIAD (ARIA) downgraded to Neutral from Buy at Chardan.
News For DRH;BOOM;FMS;HUM;JAZZ;JNPR;NIHD;PSXP;SWY;TOL;VLP;VLRS;VNO;MSO;IZEA;FST;NEM;SEAC;ITMN;SUNS;DWA;ARIA From The Last 14 Days
Check below for free stories on DRH;BOOM;FMS;HUM;JAZZ;JNPR;NIHD;PSXP;SWY;TOL;VLP;VLRS;VNO;MSO;IZEA;FST;NEM;SEAC;ITMN;SUNS;DWA;ARIA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 25, 2014
10:40 EDTITMN, ARIABiotechs rise after InterMune acquired by Roche
Subscribe for More Information
10:00 EDTITMNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:11 EDTITMNOn The Fly: Pre-market Movers
Subscribe for More Information
08:24 EDTITMNRoche to hold a conference call
CEO Schwan and CFO Hippe discuss the acquisition of InterMune on a conference call to be held on August 25 at 9 am. Webcast Link
07:11 EDTITMNInterMune volatility expected to move on Roche acquiring for $8.3B
Subscribe for More Information
06:39 EDTITMNInterMune downgraded to Hold from Buy at Stifel
Roche (RHHBY) is buying InterMune (ITMN) in a deal valued at $8.3B, or $74 per a share.
August 24, 2014
20:27 EDTITMNRoche drops pursuit for remainder of Japan's Chugai, Bloomberg says
Subscribe for More Information
13:41 EDTITMNRoche to acquire InterMune for $74.00 per share
Roche (RHHBY) and InterMune (ITMN) announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of $74.00 per share in an all-cash transaction. This corresponds to a total transaction value of $8.3B on a fully diluted basis. This offer represents a premium of 38% to InterMune's closing price on August 22 and a premium of 63% to InterMune's unaffected closing price on August 12. The merger agreement has been approved by the boards of InterMune and Roche. Under the terms of the merger agreement, Roche will commence a tender offer no later than August 29 to acquire all outstanding shares of InterMune common stock, and InterMune will file a recommendation statement containing the unanimous recommendation of the InterMune board that InterMune's shareholders tender their shares to Roche. The transaction is expected to be neutral to core earnings per share in 2015 and accretive from 2016 onwards. The acquisition of InterMune, a Brisbane, California based biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases, will allow Roche to broaden and strengthen its respiratory portfolio globally. Roche plans a smooth transition of InterMune employees and operations into the Roche organization, ensuring readiness for an expected launch of pirfenidone in the US in 2014. The closing of the transaction is expected to take place in 2014.
August 21, 2014
16:57 EDTVNOVornado JV sells Georgetown Park for $272.5M
Vornado Realty Trust announced that a joint venture owned equally by Vornado’s real estate fund and its joint venture partner, a real estate fund managed by Angelo, Gordon & Co., have sold Georgetown Park for $272.5M. Vornado owns 25% of Vornado Capital Partners. Georgetown Park is a prominent 305,000 square foot multi-level retail property located at M Street and Wisconsin Avenue in Georgetown. Vornado was responsible for developing and leasing the property, which was completely renovated and transformed, reconfiguring its floor plates to accommodate large format retail tenants with modern tenant demands.
10:14 EDTITMNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:22 EDTITMNInterMune downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded InterMune to Market Perform citing valuation.
August 20, 2014
09:46 EDTJAZZAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.
05:53 EDTITMNStocks with implied volatility movement; NGD ITMN
Subscribe for More Information
August 19, 2014
13:28 EDTJAZZJazz moves higher after WSJ report of Salix approach by Allergan
Subscribe for More Information
11:05 EDTJNPRImperva seen as takeover candidate under new CEO
Subscribe for More Information
10:13 EDTJAZZOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:42 EDTJNPRImperva new CEO has history of selling companies, says Sterne Agee
After Imperva (IMPV) appointed Anthony Bettencourt as its new CEO, Sterne Agee says that he has a history of selling companies. The firm believes that Imperva "would likely be an acquisition candidate" for a number of large tech companies such as Cisco (CSC), Juniper (JNPR), HP (HPQ), IBM (IBM), Check Point (CHKP), or F5 (FFIV). Sterne Agee believes that Imperva could be acquired for as much as $45 per share, and it keeps a Buy rating on the stock.
07:20 EDTJAZZJazz Pharmaceuticals initiated with an Overweight at JPMorgan
Subscribe for More Information
August 18, 2014
11:41 EDTJAZZCubist rises after report sparks takeover interest speculation
Subscribe for More Information
09:16 EDTDWADreamWorks Animation appoints Fazal Merchant as CFO effective September 15
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use